ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2026
[Recent advances in epidemiology, prevention and treatment of hepatitis C in China].
Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hepatitis C is a liver disease caused by the hepatitis C virus (HCV) that can lead to chronic hepatitis, cirrhosis, and hepatocellular carcinoma, and it is one of the main causes of liver disease-related deaths globally and in China. The prevention and control of hepatitis C have consistently been priorities in China. A national seroepidemiological survey conducted in 2020 showed that the weighted prevalence of anti-HCV positivity among individuals aged 1-69 years in China was 0.28%, while the weighted prevalence of HCV RNA positivity was 0.15%, corresponding to an estimated 5.54 million individuals with anti-HCV positivity and 3.22 million individuals with HCV RNA positivity. Compared with the 2006 survey, the weighted prevalence of anti-HCV positivity decreased by 35%, indicating that substantial progress has been made in hepatitis C prevention and control in China. However, due to the large population size, the absolute number of infected individuals remains considerable. The introduction of direct-acting antiviral agents (DAAs) has transformed hepatitis C into a curable disease. In recent years, the inclusion of multiple DAAs in the National Medical Insurance Drug List has improved patients' access to antiviral therapy.The National Health Commission and nine other departments jointly issued the Work Plan for the Action to Eliminate the Public Health Hazard of Hepatitis C (2021-2030) in 2021, and the National Disease Control and Prevention Administration and nine other departments jointly released the Action Plan for Viral Hepatitis Prevention and Care (2025-2030) in 2025, providing policy support and planning for hepatitis C elimination in China. This article systematically reviews the current epidemiological status, disease burden characteristics, progress in prevention and treatment, and major challenges faced, providing a reference for advancing efforts to eliminate the public health threat posed by hepatitis C based on updated epidemiological data and recent developments in prevention and treatment in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.